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Different CD3/T cell receptor monoclonal antibodies 
have distinct capacities to induce adhesion of 
T lymphocytes to endothelium
SASKIA BUYSMANN, PETER TH. A. SCHELLEKENS, WIL J. M. TAX, and INEKE J. M. TEN BERGE
AMSTERDAM and NIJMEGAN, THE NETHERLANDS
Murine CD3/T cell receptor (TCR) monoclonal antibodies (mAbs) induce immediate 
peripheral lymphocytopenias of different degree and duration. Lymphocytopenia is 
of short duration after the administration of immunoglobulin A CD3 mAb, but it 
persists much longer after the administration of immunoglobulin G2a CD3 mAb. 
Peripheral lymphocytopenia after the administration of WT31, a murine immuno­
globulin Gl TCR mAb, appears to be dependent on the polymorphism of FcvRlla. In 
high responders, lymphocytopenia is comparable to that observed after immuno­
globulin G2a CD3 mAb; in low responders, no lymphocytopenia occurs. In vitro, 
both immunoglobulin A and immunoglobulin G2a CD3 mAbs induce immediate 
activation of CDlla/CD18, with concomitant up-regulation of CDllb/CD18 on T 
cells, each of which is shown to be involved in the concurrent adhesion of T cells to 
endothelium. WT31 induces an immediate activation of CD11a/CD18 as well as T 
cell adhesion to endothelium in Fc^Rlla high responders only, interestingly without 
changes in the level of expression of CD1 lb/CD 18. We conclude that the immedi­
ate occurrence of peripheral lymphocytopenia after the administration of CD3/TCR 
mAb is mediated by changes in the level of expression or avidity (or both) of 
adhesion molecules on T cells, whereas the persistence of this lymphocytopenia 
depends on the isotype of the CD3/TCR mAb and on the presence of suitable Fc 
receptors. (J Lab Clin Med 1997;130:91-101)
Abbreviations: CLB = Central Laboratory of the Netherlands Red Cross Blood Transfusion 
Service; FACS = fluorescence-activated cell sorter; Fc-yR = Fc gamma receptor; FCS = fetal 
calf serum; FITC -  fluorescein isothiocyanate; ICAM-1 = intercellular adhesion molecule-1; 
IgA = Immunoglobulin A; lgG2a -  immunoglobulin G2a; mAb = monoclonal antibody; MFI = 
mean fluorescence intensity; MHC = major histocompatibility complex; PBMC = peripheral 
blood mononuclear cell; PBS = phosphate-buffered saline solution; PE = phycoerythrin; TCR = 
T cell receptor; VCAM-1 = vascular cell adhesion molecule-1
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M urine mAbs directed against the CD3/ 
TCR complex induce peripheral lympho­
cytopenias of different severity and dura­
tion . 1"4 Previously we investigated the kinetics of 
lymphocytopenia after treatm ent with murine CD3/ 
T C R  mAbs of the IgG2a (i.e., lX 2a and OKT3) and 
IgA class (i.e., 1XA) .1'3 lX 2a and 1XA are switch 
variant mAbs of the same idiotype and react with 
the same epitope on the CD3 molecule, whereas 
OKT3 recognizes a different epitope. Two different 
patterns of peripheral lymphocytopenia were dis­
cerned after administration of these CD3/TCR
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mAbs, depending on their isotype. Both CD3 mAbs 
of the IgG2a and IgA class induce a rapid depletion 
of lymphocytes from the peripheral blood compart­
ment, but lymphocytopenia after IgG2a CD3 mAb is 
persistent, whereas lymphocytopenia after IgA CD3 
mAb is quickly reversed .1“3 Because both IgG2a 
CD3 mAb and IgA CD3 mAb induce an immediate 
transient activation and up-regulation of adhesion 
molecules in vitro, paralleled by transient adhesion 
of T cells to a monolayer of vascular endothelial 
cells, we postulated that the mechanism of disap­
pearance of T  cells from the peripheral blood com­
partment might be the binding of these cells to the 
endothelium of the peripheral lymphoid organs.4 
The persistence of peripheral lymphocytopenia, 
then, might be mediated by at least two other, pos­
sibly cooperating, mechanisms: (1) opsonisation of 
T cells by CD3 mAb and complement, with seques­
tration of these cells in the mononuclear phagocyte 
system by means of binding to Fc and complement 
receptors; (2 ) up-regulation of the adhesion mole­
cules VCAM-1 and ICAM -1 on the endothelium 
induced by cytokines such as tumor necrosis fac- 
tor-a and interferon 7 , which are known to be re­
leased after the administration of CD3 mAb of the 
IgG2a class.5,6 The latter leads to increased adhe­
siveness of endothelium to the counterstructures 
present on peripheral blood lymphocytes.7"10 The 
murine IgA isotype switch variant CD3 mAb does 
not bind to human Fc receptors, does not activate 
lymphocytes, and hardly results in the release of 
cytokines. Moreover, monomeric murine IgA is gen­
erally assumed to have poor activating capacity for 
human complement.2,11 This may explain why ad­
ministration of this mAb in vivo induces a rapid 
lymphocytopenia that is transient.
Recently it was shown that a murine CD3/TCR 
mAb of the IgG l isotype (i.e., WT31) induces a 
long-lasting T  lymphocytopenia comparable to that 
observed after CD3 mAb of the IgG2a class only in 
70% of the patient population .12,13 This may be 
explained by polymorphism of Fc^RIIa, the human 
Fc receptor for murine IgG l, of which two allelic 
forms exist. They have been classified as Fc7 RIIa- 
H131 and F c^R IIa -R D l, according to their binding 
capacity to murine Ig G l .14 Seventy percent of the 
human population carries the Fc7RIIa-R131 form 
(high responders), whereas the other 30% of the 
population bears the Fc7RIIa-H131 form (low re­
sponders) . 15 The administration of WT31 to pa­
tients of the  high-responder phenotype induces T 
cell proliferation, cytokine release, and the occur­
rence of adverse effects. In contrast, in low-re- 
sponder patients, W T31 does not induce the release
of cytokines, does not lead to adverse effects in vivo, 
and does not stimulate lymphocytes in vitro .13,15’16 
However, it is not clear whether WT31 can activate 
or up-regulate the expression of adhesion molecules 
on lymphocytes and endothelium, as can CD3 mAbs 
of the IgG2a or IgA class, nor whether it can fix 
complement, as can IgG2a CD3 mAb.
To elucidate the role of C D lla/C D 18 and 
C D llb/C D 18 and Fc receptor binding in the patho­
genesis of lymphocytopenia, CD3/TCR mAbs of 
three different isotypes were tested on their capacity 
to activate or up-regulate expression of adhesion 
molecules on T lymphocytes in vitro and their ca­
pacity to induce adhesion of these T cells to endo­
thelial cell monolayers. Blocking experiments were 
performed to study which adhesion molecule(s) are 
involved. In addition, clinical findings were corre­
lated to our in vitro results.
METHODS
Patients. In 20 kidney transplant recipients who were 
treated prophylactic ally with either the IgG2a (lX2a) or 
the IgA (1XA) switch variant CD3 mAb—which was ad­
ministered twice daily, 0.5 mg intravenously for 10 days— 
peripheral lymphocyte counts were determined immedi­
ately before the first administration of CD3 mAb and at 
15 minutes, 30 minutes, and 1, 3, and 6 hours thereafter.2 
The first dose was preceded by 500 mg methylpred- 
nisolone and 25 mg promethazine, administered 1 hour 
before the CD3 mAh.
In addition, the number of lymphocytes in time was 
measured after the first administration of WT31 in 6 renal 
transplant recipients with acute rejection,13 The antibody 
had been purified at the Dutch National Institute of Pub­
lic Health and Environmental Protection.17 Three of these 
patients were high responders and 3 were low responders, 
as determined by in vitro T cell proliferation induced by 
WT31.15 Each of the 3 low responders and the first 
treated high responder received an initial intravenous 
dose of 6 mg WT31, whereas in the other two high re­
sponders an initial dose of 1 mg was given. In 1 out of 3 
low-responder and 2 out of 3 high-responder patients, the 
first WT31 dose was preceded by 50 mg prednisone, 
whereas the other patients did not receive any premedi­
cation.
Healthy control individuals. In 20 healthy control indi­
viduals the phenotype of Fc-yRIIa was determined on 
granulocytes and monocytes by indirect immunofluores­
cence.18 The mAbs used to discriminate Fc7RIIa-H131 
and Fc7RIIa-R131 donors were IV.3 (Medarex, Lebanon, 
N.H.), which bind both allotypic forms of Fc^RIIa, and 
41H16 (provided by Dr. B. M. Longenecker, Edmonton, 
Alberta, Canada), which selectively recognizes the Feylla- 
R131 allotype.19,20 FITC-labeled F(ab')2 fragments of 
goat anti-mouse immunoglobulin (G26M17F, CLB, Am­
sterdam, the Netherlands) were used as secondary anti-
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body. All incubations for phenotypic analysis were per­
formed in the presence of 20% (vol/vol) heat-inactivated 
(30 minutes at 56° C) human serum to avoid cytophilic 
binding of mouse mAbs. Fluorescence was quantitated 
with the flow cytometer (FACScan; Becton Dickinson, 
Mountain View, Calif.). To confirm Fc7RIIa-H131 and 
Fc7RIIa-R131 phenotypes, mononuclear cells were also 
tested in a T cell proliferation assay, with murine IgGl 
and human IgG2 anti-CD3 mAbs used as stimulants.15,18 
From these healthy control individuals 6 high responders 
and 6 low responders were selected, and peripheral blood 
was taken for in vitro studies.
Lymphocyte counts. Total leukocyte and differential 
counts were determined by flow cytometry (Technicon HI 
system; Bayer/Technicon, Tarrytown, N.Y.) in blood an­
ticoagulated with ethylenediaminetetraacetic acid.
In vitro studies: Adhesion molecule expression. Hepa- 
rinized peripheral blood samples from 12 healthy individ­
uals, 6 high responders and 6 low responders, were put in 
a waterbath of 37° C. A 5 ml sample was kept apart, and 
the remaining blood was divided into multiple aliquots, 
which were each incubated with one of the following 
mAbs in different concentrations: the murine isotype 
switch variant CD3 mAbs lX2a (IgG2a iso type) and 1XA 
(IgA isotype), the murine TCR mAb WT31 (IgGl iso­
type), and the following irrelevant murine isotype control 
antibodies: F23-49 (mouse IgG2a, directed against Myco­
bacterium tuberculosis),21 TEPC15 (mouse IgAw, myeloma 
protein; Sigma, St. Louis, Mo.), or CLB-M1451 (mouse 
IgGl, directed against plant allergens; CLB). To study 
whether the effects on expression of adhesion molecules 
were specific for antibodies directed to the CD3/TCR 
complex, the same experiments were also performed with 
murine IgG2a mAbs directed against cither the CD4 mol­
ecule (CLB-T4) or against a MHC class I antigen (W6/ 
32). At 3, 30, and 60 minutes after addition of the mAbs, 
whole blood samples were taken. PBMCs were obtained 
by centrifugation of heparinized blood on Ficoll-Paque 
(density 1.076; Pharmacia, Uppsala, Sweden). Contami­
nating erythrocytes were lysed by incubation with NH4CI 
for 10 minutes on ice, followed by 2 x washing of the 
PBMCs in PBS containing 0.5% wt/vol bovine serum al­
bumin and 0.01% wt/vol sodium azide. The PBMCs were 
incubated for 30 minutes at 0° C in PBS containing 0.5% 
wt/vol bovine serum albumin and 0.01% wt/vol sodium 
azide with appropriate dilutions of the mAb CDlla-FITC 
(Dako; clone MHM24,IgGlk), [NKI-L16]-FITC, which 
recognizes a Ca2~l'-dependent epitope on the CD1 la/ 
CD 18 complex that is expressed only on activation of 
the complex22,23 or CDllb-PE (Dako; clone 
2LPM19c,IgGlk). In addition, part of the cells was incu­
bated with the biotinylated mAb LECAM-1 (directed 
against L selectin, clone SK11, IgG2a; Becton Dickinson), 
followed by incubation with PE-labeled streptavidin (Bec­
ton Dickinson). Next, we performed two-color staining of 
these samples with a CD3 mAb to determine the total 
number of T cells. Because two-color staining with a FITC 
or PE-labeled detecting CD3 mAb might be hampered by
the in vitro bound CD3/TCR mAb, before these experi­
ments we studied which detecting CD3 mAb could be 
used for optimal detection of T cells without causing 
interference with the already bound CD3/TCR mAb. In 
the case of WT31, at any concentration tested, two-color 
staining was possible with CD3-PE or CD3-FITC (both 
from Becton Dickinson; Leu-4; clone SK7, IgGl). In ex­
periments with lX2a and 1XA, two-color staining was 
optimal when using a mixture of directly labeled CD4 and 
CD8 mAb. In control experiments, the mixture of these 
CD4 and CD8 mAbs (Becton Dickinson; Leu-3 a; clone 
SK3, IgGl and Leu-2a; clone SKI, IgGl, respectively) was 
shown to detect numbers of T cells equal to the number 
detected by the Leu-4 mAb. Determination of the total 
number of CD3+ cells was performed by a direct labeling 
procedure with Leu-4-FITC (Becton Dickinson).
The same experiments were performed on PBMCs in­
cubated with CD3/TCR mAbs after their isolation from 
whole blood by Ficoll density gradient centrifugation.
Analysis of cell suspensions was done on FACScan 
(Becton Dickinson). Lymphocytes in the PBMC popula­
tion were gated on forward and sideward scatter.
Functional adhesion studies. Functional adhesion stud­
ies were performed in parallel with the above-described 
assays. PBMCs from the same 12 healthy control individ­
uals were washed 3 times in Tris-buffered Earle’s bal­
anced salt solution containing 5% FCS. CD3+ cells were 
obtained as follows: B lymphocytes, monocytes, and nat­
ural killer cells were removed by incubation with murine 
mAb anti-CD19 (CLB, clone 11G1), anti-CD14 (CLB, 
clone 8G3), and anti-CD16 (CLB, gran-1) followed by 
incubation with sheep-anti-mouse IgG-coated Dynabeads 
(N-0212; Dynal A.S., Oslo, Norway). This procedure re­
sulted in >95% pure CD3+ cell populations, as was con­
firmed by FACS analysis after staining with FITC-labeled 
CD3- and PE-iabeled CD16 and CD56 mAbs (NK-Simul- 
set; Becton Dickinson). CDV  cells were resuspended and 
adjusted to a concentration of 2 x 106 cells/ml and incu­
bated on ice for 30 minutes with either lX2a, tXA, WT31, 
CLB-T4, W6/32, or the irrelevant isotype control antibod­
ies F23-49, TEPC15, and CLB-M1451 in the indicated 
concentrations. Phorbol myristate acetate PMA, 50 ng/ml 
(Sigma), was used as a positive control. Next, the cells 
were washed 2 times at 4° C with Iscove’s modified Dui- 
becco’s medium containing 5% FCS. Because cross-link­
ing is assumed to occur in vivo after the administration of 
CD3 mAb of the IgG2a class and after administration of 
WT31 to patients with the high-responder phenotype, 
adhesion studies were also performed after cross-linking 
of the mAb-coated CD3/TCR complex with goat-anti- 
mouse Ig. Therefore, after incubation with the T cell 
mAb, one half of the cell suspension was cross-linked by 2 
lig/ml goat anti-mouse Ig (GM17D, CLB), immediately 
followed by 3 minutes of 10 g centrifugation at 37° C; no 
goat-anti-mouse Ig was added to the other half 24 Then 25 
jxl of these cell suspensions was added to a monolayer of 
an immortalized endothelial cell line, which is derived 
from human umbilical vein endothelial cells,25 and was
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cultured in 96-well plates (Nunclon Micro Well F96; Nunc 
A.S., Roskilde, Denmark) on 1% gelatin (G1890; Sigma) 
in PBS. The remaining part of the cell suspensions was put 
in a shaking waterbath at 37° C, from which samples were 
added to endothelial cell monolayers after 30 and 60 
minutes. The 96-well plates were incubated for 15 minutes 
at 37° C (5% C02). Then the nonadherent fraction was 
removed by washing three times with 200 jxl of 37° C 
Earle’s balanced salt solution containing 5% FCS. The 
adherent fraction was stained with Diff-Quick (i.e., a 
three-step staining set consisting of [1] fixation in metha­
nol with fast green, 0.002 gm/L; [2] eosin G in phosphate 
buffer, pH 6.6; and [3] thiazine dye in phosphate buffer, 
pH 6.6 [Baxter Dade A.G, Diidingen, Switzerland]). All 
experiments were performed in triplicate.
Blocking studies were performed with mAbs directed 
against either the common ß2 integrin chain (CD 18: TS 
1/18,26 against CD lia  [NKI-L7]27 or against CDllb 
[Bear-1]28) in a final concentration of 10 fJLg/mi, which was 
added to the endothelial cell monolayer simultaneously 
with the T cells that had been incubated with the different 
CD3/TCR mAbs for 3 minutes at 37° C. This concentra­
tion of 1.0 (xg/ml had shown in previous studies to result in 
a maximal inhibition of adhesion.
The adhesion was scored blindly by 3 technicians inde­
pendently in a semiquantitative way (score ranging from 0 to 
5; 0 = no T cells adherent to endothelium; 1 = <50 T 
cells/field; 2 -  50 to 100 T cells/field; 3 = 100 to 250 
T cells/field; 4 = 250 to 350 T cells/field; 5 = >350 T 
cells/field; scored at a magnification of X200).
With therapeutic plasma levels considered to be about 
1 fig/ml, the studies on expression of lymphocyte adhesion 
molecules as well as the adhesion studies were performed 
with different concentrations of the mAb, as follows: for 
WT31, 0.01, 0.1,1  and 10 jjug/ml; for lX2a and 1XA, 0.01, 
0.1, 1 and 5 jxg/ml.
T cell binding studies. Differences between the three T  
cell mAbs in their binding to T cells might influence the 
degree of activation or up-regulation of adhesion mole- 
cules. Therefore, the T cell binding of the three mAbs was 
analyzed as follows: PBMCs from 4 healthy control 
individuals were isolated by Ficoll-density gradient cen­
trifugation and incubated for 30 minutes on ice with 
lX2a, 1XA, WT31, or the irrelevant murine isotype 
control antibodies in a concentration ranging from 0 to 
4 [lg/ml. The cells were washed, and subsequently PE- 
labeled rabbit F(ab')2 anti-mouse Ig was added (code R 
0439; Dako, Glostrup, Denmark) at multiple dilutions 
ranging from 1:5 to 1:160. After 30 minutes of incuba­
tion on ice, the cells were washed and the MFI was 
measured by FACS analysis with a gate to identify the 
lymphocyte fraction. Because binding of the detecting 
rabbit F(ab')2 anti-mouse I g may be different for the 
diverse murine isotype mAbs, the actual measured MFI 
values cannot be compared. Therefore, the concentra­
tion of T cell mAb that was needed to reach a 50% 
value of the maximal level in MFI was used as a mea­
sure for T cell binding.
Complement studies. The ability of each of the three T 
cell mAbs to induce binding of C3 activation products on 
T cells was determined by FACS analysis. Heparinized 
whole blood samples from 6 healthy high-responder and 6 
healthy low-responder control individuals were incubated 
for 15 minutes at 37° C with 1 |ig/ml lX2a, 1XA, WT31, or 
the irrelevant murine isotype control antibodies. Mono­
nuclear cells were isolated by centrifugation on Ficoll- 
paque. Deposition of C3 activation products on T cells 
was detected with a biotinylated mAb directed against a 
neo-epitope on C3b, C3bi, and C3c (C3-28, CLB29), fol­
lowed by a second incubation step with PE-labeled 
streptavidin and a third incubation with a FITC-labeled 
CD 3 mAb (Leu-4; Becton Dickinson).
Calculations and statistical analysis
Absolute number of double-positive cells. The percentage of 
double-positive cells was calculated by means of PCLYSYS 
software from Becton Dickinson and was multiplied times 
the absolute number of lymphocytes at the same time point, 
resulting in the absolute number of double-positive cells. All 
values are expressed as mean ± SEM.
MFI measurements. At all time points the MFI was 
calculated with PCLYSYS software. All values are ex­
pressed as mean ± SEM.
RESULTS
Lymphocytopenia after in vivo administration of differ­
ent CD3/T ceil mAbs. Administration of either lX 2a or 
1XA induced a disappearance of virtually all T lym­
phocytes from the peripheral blood compartment 
within 15 minutes. However, CD3 depletion after 
1XA was of shorter duration than that after lX2a 
administration; whereas at least during the first 2 
days of IgG2a treatment the number of CD3+ cells 
remained low as compared with pretreatment val­
ues, lXA-induced T  cell depletion lasted for several 
hours only .1,2 After administration of the IgGl TCR 
mAb WT31, the occurrence of a peripheral lympho­
cytopenia appeared to be dependent on the Fey 
receptor Ila  status of the patient receiving WT31. 
Also, in high-responder patients an immediate and 
long-lasting disappearance of lymphocytes was ob­
served after the administration of WT31, whereas in 
low-responder patients the number of peripheral 
blood lymphocytes remained unchanged (data not 
shown). On the basis of these results, two phases with 
different underlying pathogenetic mechanisms can be 
distinguished in the CD3/TCR mAb-induced periph­
eral T  lymphocytopenia: (1) an immediate decline in 
the number of peripheral T lymphocytes and (2) per­
sistence of the peripheral lymphocytopenia.
In vitro effects of CD3/TCR mAbs
Expression o f adhesion molecules in vitro
m A b s  d i r e c t e d  a g a i n s t  CD3. In each of the 12 
healthy control individuals, the addition of 1 |xg/ml
J Lab Clin Med
Volume 130, Number 1 Buysmann et al.
o>O
w
07
O
or"
E
+
CO
O
O+CD
to
_ Q
CO
1.25 -
1.00 -
0.75 -
0.50 -
°  0.25 *
0 .0 0  -
0 3 30 60
A time (minutes)
0
.5co>
■ Mc
a>£
+-»<o0
I
a)
k _
- Q
Q
O
LL
B time (minutes)
Fig. 1. Comparison of the effect of lX2a, 1XA, and WT31 in high responders or WT3I in low responders 
on the expression of NKI-L16 (directed against the activated form of CD 11 a/CD 18) and CD lib on 
peripheral blood T lymphocytes from healthy control individuals. Depicted are the number of NKI- 
L16+CD3+ lymphocytes (A) and the MFI of CD lib on CD3+ T cells, presented as a percentage of the 
preaddition value (B) after the administration of 1 jig/ml of either lX2a (A, n = 12), 1XA (H, n = 12), 
or WT31 to whole blood samples of high responders (♦, n = 6) or low responders (# , n = 6). Open 
symbols show the effect of 1 (xg/ml of the irrelevant murine control monoclonal antibodies of the IgG2a 
(A), IgA (□), or IgGl (O) isotype. Results are represented as mean ± SEM.
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Fig. 2. Comparison of the effect of 1 jxg/ml 1X2a, 1XA, or WT31 
in high responders or WT31 in low responders on the capacity to 
induce adhesion of purified T  cells to monolayers of endothelial 
cells (open bars) and blocking of this adhesion by mAbs against 
C D lla  (hatched bars) against CD 18 (solid bars) or against CD l i b  
(cross-hatched bars). These results were obtained after 3 minutes 
of incubation with the respective CD3/TCR mAbs, without cross- 
linking by goat-anti-mouse Ig. Results are represented as mean ±  
SEM for 6 healthy high responders and 6 healthy low responders 
for WT31 and for all 12 individuals for lX2a and 1XA.
lX 2a or 1XA to whole blood induced an immediate 
increase in the number of T cells bearing the acti­
vated form of CDlla/CD18, as detected by NKI- 
L16 expression, and an up-regulation of the C D llb /  
CD18 molecule (Fig. 1).
m A b s d i r e c t e d  a g a i n s t  t h e  TCR. Incubation of 
whole blood from 6 healthy high responders with 1 
jxg /m l WT31 induced an immediate increase in the 
number of NKI-L16-positive T cells. In contrast, no 
change was observed after the addition of WT31 to 
whole blood from 6 healthy low responders (Fig. 1, 
A ).  No changes in CD 'llb expression were observed, 
either in the high responders or in the low respond­
ers, while the addition of 1 jjig/ml lX 2a or 1XA in 
the same experiments did induce an increase in 
C D llb  expression (Fig* 1, B). No effects on L- 
selectin expression, either in percentage of positive 
cells or in mean fluorescence intensity, were ob­
served on CD3+ T  cells after the addition of either 
1XA, lX2a, or WT31. Incubation of whole blood 
with 1 |Ag/ml of the irrelevant murine mAbs of the 
IgG2a, IgA, or IgG l isotype did not alter the ex­
pression of NKI-L16 or C D llb  (Fig. 1, A  and B ), 
nor did incubation with the CD4 or the M HC class
I mAb (data not shown). Dose-response studies 
showed a maximal effect on NKI-L16 and C D llb  
expression at a concentration of 1 jjig/ml for lX 2a or
1XA. Regarding WT31, increasing the concentra­
tion to 10 p,g/ml had only a small additional effect 
on NKKL16 expression in high responders but did 
not affect the NKI-L16 expression in low respond­
ers, Even at this high concentration of WT31, no 
changes in C D llb  expression were observed in high 
responders or low responders (data not shown). 
W hen similar experiments were performed on 
PBMCs instead of whole blood, the same results 
were obtained (data not shown).
Functional adhesion studies. Purified T cells from 
each of the 12 healthy control individuals showed an 
immediate adhesion to endothelial cell monolayers 
after incubation for 3 minutes with 1 |xg/ml lX 2a or 
1XA (Fig. 2). For WT31, a discrimination could be 
made between high responders and low responders: 
in high responders, incubation with 1 |xg/ml WT31 
also induced adhesion of T cells to endothelium, 
whereas no T  cell adhesion could be detected in the 
low-responder group, when adhesion was studied 
without cross-linking (Fig. 2). The irrelevant murine 
isotype control antibodies, the CD4, or the MHC 
class I mAbs also did not affect adhesion of T cells 
to endothelial cell monolayers (not shown). Incuba­
tion with 50 ng/ml phorbol myristate acetate, used as 
a positive control, resulted in an adhesion score of 
3.75 ±  0,22 after 3 minutes. Dose-response curves 
showed that the T cell mAb-induced adhesion was 
dose dependent. A  maximal adhesion was observed 
with 1 |ULg/ml of each of the three mAbs tested. For 
WT31, increasing the dose to 10 jjLg/ml still did not 
result in adhesion of T cells to endothelial cell 
monolayers in the low-responder group. Adhesion 
blocking studies showed that coincubation with ei­
ther a C D l l a  or a CD18 mAb completely inhibited 
the adhesion observed after 3 minutes of incubation 
with either lX 2a, 1XA, or WT31. However, coincu­
bation with a C D llb  mAb resulted in partial inhi­
bition of the CD3 mAb-induced adhesion but did 
not suppress the WT31-induced adhesion (Fig. 2). 
Studies in which incubation with the T cell mAb was 
followed by cross-linking with goat-anti-mouse Ig 
showed that with each of the three mAbs, subse­
quent cross-linking resulted in higher adhesion 
scores as compared with preincubation with the 
same m Ab w ithout cross-linking. A fter cross-link- 
ing, adhesion was also induced by WT31 in the 
low responders  (data not shown). For the CD3 
mAbs lX 2 a  and 1XA, adhesion was maximal after 
3 m inutes of cross-linking at 37° C, followed by a 
decrease. F o r  WT31, maximal adhesion was ob­
served after 30 minutes of cross-linking, both in 
high responders  and in low responders (data not 
shown).
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Fig. 3. Affinity of lX2a (A), 1XA (HI), and V/T31 ( • )  for T cell binding, as detected by FACS analysis. 
Depicted is the MFI of PE-labeled rabbit F(ab' ) 2 fragments-anti-mouse Ig. The data of one representative 
out of four experiments is shown.
T cell binding studies. Fig. 3 shows a difference in 
T cell binding between the CD3 mAbs lX2a and 
1XA on the one hand and WT31 on the other hand. 
When an optimal dilution (1:10) of the detecting 
PE-labeled rabbit F(ab ')2 anti-mouse Ig conjugate 
was used, for the CD3 mAbs lX2a and 1XA a 50% 
value of the maximal MFI could already be reached 
at concentrations of 41.5 and 76.5 ng/ml, respec­
tively, whereas for WT31 a higher concentration 
(585 ng/ml) was needed. This suggests that WT31 
has a lower affinity for binding to the CD3/TCR 
complex than do the switch variant CD3 mAbs lX2a 
and 1XA.
Complement activation. Fixation of C3 activation 
products on T cells could be observed only after 
incubation of whole blood with the IgG2a mAb 
lX2a, not after incubation with the IgA switch vari­
ant 1XA or the IgG l TCR mAb WT31 (Fig. 4). 
Increasing the 1XA or WT31 dose to 10 jxg/ml still 
could not induce any fixation of C3 activation prod­
ucts on T  cells. No differences were observed be­
tween high responders and low responders concern­
ing the ability to induce deposition of C3 activation 
products on T cells (not shown).
DISCUSSION
To interpret the CD3/TCR niAb-induced lym­
phocytopenia in our different patient groups, the 
preadministered corticosteroid dose has to be taken 
into account. To diminish first-dose side effects, the 
first administration of CD3/TCR mAb is generally 
preceded by the administration of a single dose of 
corticosteroids, which are known to induce a revers­
ible peripheral lymphocytopenia by themselves.30,31 
This lymphocytopenia starts 30 minutes after corti­
costeroid administration and reaches its maximum 
effect in about 6 hours.30,31 For this reason it is 
unlikely that corticosteroids have something to do 
with the immediate decline in peripheral T lympho­
cytes after CD3/TCR mAb administration. How­
ever, persistence of the lymphocytopenia might be 
modified by corticosteroids. In chimpanzees, admin­
istration of the IgA switch variant CD3 mAb without 
corticosteroid premedication induced a clear saw-
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Fig. 4. Fixation of C3 activation products on T cells after incubation of heparinized whole blood from a 
healthy high responder for 15 minutes at 37° C with 1 (xg/ml lX2a, 1XA, WT31, or the irrelevant isotype 
control antibodies. FL-1 depicted on the x  axis represents binding of a FITC-labeled CD3 mAbs; FL-2 
depicted on the y axis represents binding of the biotinylated C3-28 mAb (which recognizes C3 activation 
products) as detected with PE-labeled streptavidin.
tooth curve with respect to the number of T cells: a 
very fast decline and an almost complete recovery 
within 24 hours .1 This effect is also visible in human 
subjects on day 8 of the treatment with the IgA 
switch variant mAb CD3. On day 1 the recovery is 
partial but clearly present, and is apparently modi­
fied by pretreatment with high-dose corticoste­
roids .2 For the reasons mentioned we feel it justified 
to  discuss patterns of CD3 lymphocytopenia even 
after corticosteroid administration.
Theoretically, three mechanisms may be involved 
in the CD3/TCR mAb-induced disappearance of T  
lymphocytes from the peripheral blood compart­
ment: (1) activation up-regulation (or both) of ad­
hesion molecules on lymphocytes resulting in adhe­
sion to vascular endothelium; (2) Fc-Fc receptor 
interaction with activation of mononuclear cells re­
sulting in systemic cytokine release and leading to 
up-regulation of adhesion molecules on vascular en­
dothelium; (3) interaction of the Fc part of the mAb 
with an appropriate Fc receptor or coating of T cells 
by complement activation products (or both inter­
action and coating), giving rise to sequestration of 
the cells in the mononuclear phagocyte system, 
eventually followed by lysis of these cells. However, 
in a previous article we presented arguments that 
make it unlikely that cell lysis is a major mechanism 
in the observed lymphocytopenia.32
On account of the observations in vivo, two 
phases can be discerned in the peripheral lympho­
cytopenia after CD3/TCR mAb, and these may have 
different underlying pathogenetic mechanisms 
(summarized in Table I). For antibodies that induce 
an immediate decline in the number of T lympho­
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Table I. Summary of in vitro effects of CD3/TCR mAb
mAb
Peripheral T 
lymphocytopenia
Expression of 
adhesion molecules
Number of MFI of 
(NKI-L16)+ C D llb  on 
T cells T cells
Adhesion to 
endothelium 
without 
cross-linking
Effect of inhibitory mAb
Suitable Fc 
receptors 
available
Complement 
fixation on 
T cells
C D lla
mAb
CD18
mAb
C D llb
mAb
1X2a Immediate, long lasting 1 1 1 1 1 +  +  + Total Total Partial Yes Yes
1XA Immediate, short lasting 1 1 1 1 +  + Total Total Partial No No
WT31 HR Immediate, long lasting î  t --- +  + Total Total No Yes No
WT31 LR No lymphocytopenia --- --- — ND ND ND No No
ND, Not determined.
cytes, the common denominator is that they induce 
both activation and an increase in expression of 
adhesion molecules in vitro. CD3 mAbs of either the 
IgG2a or the IgA isotype were able to induce a 
transient adhesion of T cells to endothelial cells, and 
this could completely be blocked by either a C D lla  
or CD18 mAb and partially by a C D llb  mAb. 
Therefore, activation of the CDlla/CD18 molecule 
seems to be a prerequisite for the CD3 mAb-in­
duced T  cell adhesion to endothelium, but increased 
expression of C D llb  may be needed for optimal 
CD3 mAb-induced adhesion. WT31 could induce 
adhesion of T cells from high responders to endo­
thelium without apparent involvement of C D llb . 
Because administration of WT31 in vivo to high 
responders is able to induce an immediate periph­
eral T cell lymphocytopenia, we conclude that up- 
regulation of the CDllb/CD18 molecule is not es­
sential for the induction of such a peripheral T 
lymphocytopenia. In low responders, the WT31 
mAb appeared to induce neither activation nor up- 
regulation of adhesion molecules on T cells. In 
agreement with this observation, no immediate pe­
ripheral lymphocytopenia was observed after WT31 
administration to low responder patients.
The difference in ability to induce an up-regula­
tion of C D llb  between CD3 mAbs and the TCR 
mAb WT31 is difficult to explain. Because each of 
the studied mAbs binds to the CD3/TCR complex, a 
difference in intracellular signal transduction is un­
likely to be responsible. The lower affinity of WT31 
as compared with that of the CD3 mAb for their 
respective ligands may play a role in the observed 
differences, although other yet-unknown factors 
may be involved as well. In vivo up-regulation of 
C D llb/C D 18 probably results from a direct signal­
ing pathway that is initiated by binding of CD3/TCR 
mAbs to the CD3/TCR molecule and leads to stim­
ulation of the inositol phospholipid metabolism, 
thereby giving rise to activation of protein kinase C 
and Ca2+ fluxes, which in turn may lead to up-
regulation of CDllb/CD18 expression on T  
cells.33,34 Although 1XA is a nonactivating mAb, it is 
able to induce Ca2+ mobilization in peripheral 
blood T lymphocytes,35 which may be involved in the 
observed activation of CDlla/CD18 and increased 
expression of CDllb/CD18.
The common denominator for antibodies that in­
duce persistence of peripheral lymphocytopenia is 
interaction of the Fc part of the mAb with an ap­
propriate Fc receptor. Indeed, persistence is not 
observed after administration of 1XA to all patients 
or WT31 to low responders, corresponding with the 
absence of an appropriate Fc receptor for these 
mAbs. Various mechanisms may be responsible for 
the Fc receptor-mediated decline in peripheral T 
lymphocytes. Binding of the Fc part of the mAb to 
its Fc receptor can lead to sequestration of lympho­
cytes in the mononuclear phagocyte system. In ad­
dition, interaction of the Fc part of the CD3/TCR 
mAb on T cells with its Fc receptor on mononuclear 
cells induces activation of the latter, resulting in the 
release of cytokines such as tumor necrosis factor-a 
and interferon-7 . Indeed, a systemic cytokine re ­
lease has been observed after the administration of 
IgG2a CD3 mAb or WT31 to high responders, 
whereas only a minimal amount of tumor necrosis 
factor-a was observed after WT31 administration to 
low responders or after the administration of 
1XA 2,5,6,13 These cytokines have been shown to 
induce an up-regulation of ICAM-1 and VCAM-1 on 
the vascular endothelium in vitro, resulting in in­
creased adherence of T cells to endothelium.7,8'36 Be­
cause WT31 does not induce any complement activa­
tion and persistence of the lymphocytopenia is still 
observed after the administration of this mAb to high- 
responder patients, it seems justified to conclude that 
complement activation is certainly not an essential 
mechanism for this efect to occur. Whether activation 
of the complement system only would be sufficient for 
persistence of lymphocytopenia cannot be concluded 
from the current experiments.
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In conclusion, two different phases can be distin­
guished in the CD3/TCR-induced T lymphocytope­
nia. The first phase of immediate disappearance can 
be explained by activation or increased expression 
(or both) of adhesion molecules. This seems to be 
sufficient to induce an immediate decline in periph­
eral T cells in vivo. The second phase of persistence 
of the peripheral lymphocytopenia is directly depen­
dent on the heavy chain of the mAb and the pres­
ence of an  appropriate Fc receptor for this mAb.
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